/NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
VANCOUVER, BC, Jan. 20, 2023 /CNW/ – PanGenomic Well being Inc. (“PanGenomic Well being” or the “Firm”) (CSE: NARA), is happy to announce the gentle launch of the “NARA DNA Stories” characteristic obtainable by way of its web site nara.care. The Firm has launched its first report of a sequence, the NARA MIND Report as its debut product which could be bought for $189.00 USD. Moreover, the Firm introduced immediately that, additional to its information launch on December 23, 2022, it has closed the ultimate tranche (the “Remaining Tranche”) of its oversubscribed non-public placement providing (the “Providing”) of models (every a “Unit”) at a worth of $0.15 per Unit, for whole gross proceeds beneath the Providing of $512,250. Lastly, the Firm additionally introduced that it has retained Pulse Investor Relations Providers Inc. (“PulseIR”) to supply digital advertising and marketing companies for investor relations.
Nara DNA Stories
The NARA MIND Report will present customers with distinctive tailor-made psychological well being insights that cowl their genetic disposition, micronutrient sensitivity, pure complement susceptibility profile and metabolic weight loss plan report.
Nara generates the customized DNA Report by performing an evaluation of a person’s distinctive DNA sequences which can be particularly related to key genes associated to psychological well being. With extra private data on the customers disposal by way of such insights and stories, the Firm believes that customers will have the ability to take proactive steps in direction of bettering their well being.
“I’m extraordinarily happy to be asserting this new characteristic as a part of PanGenomic’s resolution to customized data-based various care,” said Maryam Marissen, CEO and President of PanGenomic Well being Inc. “The NARA DNA Stories characteristic will likely be expanded to incorporate quite a lot of different customized DNA stories within the coming months.”
Oversubscribed Providing and Train of Beforehand Issued Warrants
The Firm additionally introduced that, additional to its information launch on December 23, 2022, the Firm closed the ultimate tranche (the “Remaining Tranche”) of its oversubscribed non-public placement providing (the “Providing”) of models (every a “Unit”) at a worth of $0.15 per Unit, for whole gross proceeds beneath the Providing of $512,250.
Every Unit beneath the Providing consists of 1 (1) Class A Frequent share (every, a “Share”) of the Firm and one (1) Class A Frequent share buy warrant (every, a “Warrant”). Every Warrant is exercisable for one further Share at an train worth of $0.30 for a interval of 24 months from the date of subject. If the closing worth of the Shares on the Canadian Securities Change is larger than or equal to $0.60 for 10 consecutive buying and selling days, the Firm has the fitting to speed up the expiration date of the Warrants. Warrant holders will likely be notified of the Firm’s train of the acceleration proper by information launch, and can thereafter have a 30-day interval to train the Warrants.
The Remaining Tranche beneath the Providing consisted of two,081,667 Models for gross proceeds of $312,500. Mixed with the primary tranche, the Providing has resulted in whole gross proceeds of $512,250 from the issuance of three,415,000 Models. In reference to closing of the Remaining Tranche, the Firm paid a registered dealer a money payment of $750. The Firm will use the online proceeds from the Providing to proceed the event and advertising and marketing of its Nara, Mindleap and PlantGx merchandise and for common working capital functions.
All securities issuable in reference to the Remaining Tranche are topic to a statutory maintain interval beneath relevant securities legal guidelines of 4 months and in the future from the date of subject.
Along with closing the Providing, the Firm can be happy to report that roughly 95% of warrants beforehand issued by the Firm having an train worth of $0.10 per Share had been exercised previous to their warrant expiry date of January 13, 2023. The Firm raised roughly $409,000 from the train of those warrants.
This press launch doesn’t represent a proposal to promote or a solicitation of a proposal to purchase any the securities of the Firm in the US. The securities supplied by the Firm haven’t been and won’t be registered beneath the US Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities legal guidelines and is probably not supplied or offered inside the US or to U.S. Individuals until registered beneath the U.S. Securities Act and relevant state securities legal guidelines, or an exemption from the registration necessities thereof is offered.
Engagement of PulseIR
The Firm additionally introduced that it has retained Pulse Investor Providers Inc. (“PulseIR”) to supply digital advertising and marketing companies for investor relations. Underneath the phrases of its settlement, PulseIR will present its cell pockets move investor relations platform at a complete value to the Firm of $120,000 for an preliminary contract time period of twelve months starting January 16, 2023. PulseIR participated within the Providing by subscribing for 840,000 Models at an mixture worth of $126,000.
PulseIR is a digital advertising and marketing and advisory companies agency based mostly in Vancouver, BC, that makes a speciality of offering its mobile-first, social-centric, neighborhood platform for investor relations. Upon getting into into of this new settlement with PulseIR, the Firm terminated the capital markets advisory and digital advertising and marketing companies contract with Bello Capital Companions, which was beforehand introduced on January 3, 2023. No termination charges had been paid by the Firm.
About PanGenomic Well being
PanGenomic Well being is a precision well being firm that has developed a self-care digital platform to ship customized, evidence-based details about pure therapies. The Firm’s preliminary focus is to assist psychological well being. Registered as a British Columbia profit firm, PanGenomic Well being’s mission is to advertise and enhance the well being and wellness of individuals and society by offering a expertise platform that identifies plant-based options tailor-made to the well being profile of every particular person.
This information launch consists of sure statements that could be deemed “forward-looking statements”, together with statements respecting the companies to be offered by PanGenomic and the consideration to be paid to PanGenomic. The usage of any of the phrases “anticipate”, “proceed”, “estimate”, “count on”, “could”, “will”, “would”, “mission”, “ought to”, “imagine” and related expressions are supposed to determine ahead trying statements. Though PanGenomic believes that the expectations and assumptions on which the forward-looking statements are based mostly are affordable, undue reliance shouldn’t be positioned on the forward-looking statements as a result of PanGenomic may give no assurance that they are going to show to be appropriate. Since forward-looking statements handle future occasions and situations, by their very nature they contain inherent dangers and uncertainties. These statements converse solely as of the date of this Information Launch. Specifically, there isn’t a assurance that the Firm will have the ability to promote any further securities beneath the Providing. Precise outcomes might differ materially from these presently anticipated as a consequence of various elements and dangers together with varied danger elements mentioned in PanGenomic’s disclosure paperwork which could be discovered beneath PanGenomic’s profile on www.sedar.com.
The Canadian Securities Change has neither permitted nor disapproved the data contained herein and doesn’t settle for duty for the adequacy or accuracy of this information launch.
SOURCE PanGenomic Well being Inc.
For additional data: please contact: Jerry Lai, Investor Relations, PanGenomic Well being Inc., 778 743 4642, [email protected]; Maryam Marissen, President & CEO, PanGenomic Well being Inc., 778 743 4642, [email protected]; Pulse Investor Providers Inc., 541 Howe Road, 2nd Fl., Vancouver, BC V6C 2C2, 1 877-754-5336, [email protected]